FADS2 and acute myeloid leukemia: When combined with ven + aza, treatment with the FADS1/2 inhibitor significantly decreased viability in both de novo and relapsed ROS-Low primary AML cells, while FADS2 inhibition significantly decreased viability only in de novo cells.